SEARCH

SEARCH BY CITATION

References

  • 1
    Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55: 1-23.
  • 2
    Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis—United States, 2007. MMWR Surveill Summ 2009; 58: 1-27.
  • 3
    Bulkow LR, Wainwright RB, McMahon BJ, Middaugh JP, Jenkerson SA, Margolis HS. Secular trends in hepatitis A virus infection among Alaska Natives. J Infect Dis 1993; 168: 1017-1020.
  • 4
    Bialek SR, Thoroughman DA, Hu D, Simard EP, Chattin J, Cheek J, et al. Hepatitis A incidence and hepatitis a vaccination among American Indians and Alaska Natives, 1990-2001. Am J Public Health 2004; 94: 996-1001.
  • 5
    Singleton RJ, Hess S, Bulkow LR, Castrodale L, Provo G, McMahon BJ. Impact of a statewide childhood vaccine program in controlling hepatitis A virus infections in Alaska. Vaccine 2010; 28: 6298-6304.
  • 6
    CDC. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996; 45: 1-30.
  • 7
    CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48: 1-37.
  • 8
    Dagan R, Amir J, Mijalovsky A, Kalmanovitch I, Bar-Yochai A, Thoelen S, et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 2000; 19: 1045-1052.
  • 9
    Fiore A, Shapiro C, Sabin K, Labonte K, Darling K, Culver D, et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J 2003; 22: 354-359.
  • 10
    Letson GW, Shapiro CN, Kuehn D, Gardea C, Welty TK, Krause DS, et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr 2004; 144: 327-332.
  • 11
    Siegrist CA. The challenges of vaccine responses in early life: selected examples. J Comp Pathol 2007; 137 Suppl 1: S4-S9.
  • 12
    Bell BP, Negus S, Fiore AE, Plotnik J, Dhotre KB, Williams J, et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J 2007; 26: 116-122.
  • 13
    Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002; 109: 839-845.
  • 14
    Yuan YC. Multiple Imputation for Missing Data: Concepts and New Developments (Version 9.0). Rockville, MD; SAS Institute Inc.
  • 15
    Lieberman JM, Chang SJ, Partridge S, Hollister JC, Kaplan KM, Jensen EH, et al. Kinetics of maternal hepatitis a antibody decay in infants: implications for vaccine use. Pediatr Infect Dis J 2002; 21: 347-348.
  • 16
    Byrd K, Bruden D, Michael B, Bulkow L, Zanis C, Snowball M, et al. Long-term immunogenicity of inactivated hepatitis A vaccine: follow-up at 15 years. J Pediatr Infect Dis 2010; 5: 321-326.
  • 17
    Karetnyi Iu V, Kuzin S, Sychev AV, Balaian MS. Transplacental antibodies to hepatitis A virus [in Russian]. Vopr Virusol 1988; 33: 86-88.
  • 18
    Rendi-Wagner P, Korinek M, Mikolasek A, Vecsei A, Kollaritsch H. Epidemiology of travel-associated and autochthonous hepatitis A in Austrian children, 1998 to 2005. J Travel Med 2007; 14: 248-253.
  • 19
    Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, Van Herck K, Shouval D, et al. Hepatitis A booster vaccination: is there a need? Lancet 2003; 362: 1065-1071.
  • 20
    Bian GL, Ma R, Dong HJ, Ni HX, Hu FJ, Chen YR, et al. Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine 2010; 28: 4798-4801.
  • 21
    Lopez EL, Contrini MM, Mistchenko A, Debbag R. Long-term immunity after two doses of inactivated hepatitis A vaccine, in Argentinean children. Pediatr Infect Dis J 2010; 29: 568-570.
  • 22
    Beran J. Bivalent inactivated hepatitis A and recombinant hepatitis B vaccine. Expert Rev Vaccines 2007; 6: 891-902.
  • 23
    Diaz-Mitoma F, Law B, Subramanya A, Hoet B. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine 2008; 26: 1759-1763.
  • 24
    Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171( Suppl. 1): S44-S49.
  • 25
    Nalin DR, Kuter BJ, Brown L, Patterson C, Calandra GB, Werzberger A, et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol 1993; 18( Suppl. 2): S51-S55.